Business Context and Reporting Period
Company: Coherus BioSciences, Inc. (CHRS)
Filing Type: Form 8-K (Current Report)
Date: March 4, 2025
Event: Supplemental disclosures regarding the proposed sale of the UDENYCA (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals Ltd. ("Purchaser"). The filing addresses stockholder litigation alleging disclosure deficiencies in the definitive proxy statement filed on January 28, 2025, for a special meeting scheduled for March 11, 2025.
Key Financial Metrics and Transaction Valuation
Transaction Consideration: Approximately $530 million implied value, comprising:
- Up-front Consideration: Approximately $483 million (excluding earnout payments).
- Risk-Adjusted NPV of Earnout: Approximately $47 million (based on maximum earnout of $75 million, probability estimates, and a 13.25% discount rate).
UDENYCA Business Projections (Unlevered Free Cash Flow):
| Year Ended Dec 31 | 2025E | 2026E | 2027E | 2028E | 2029E | Terminal |
|---|---|---|---|---|---|---|
| Revenue ($M) | 186 | 264 | 255 | 245 | 240 | 180 |
| Gross Profit ($M) | 115 | 187 | 188 | 179 | 174 | 135 |
| EBIT ($M) | 68 | 142 | 155 | 146 | 141 | 110 |
| Unlevered FCF ($M) | 51 | 98 | 116 | 110 | 105 | 88 |
Valuation Multiples (J.P. Morgan Analysis):
- Public Trading Multiples (FV/2025E Revenue): Reference range 1.1x to 5.7x. Implied FV range: $205 million to $1,060 million.
- Selected Transactions (FV/LTM Revenue): Reference range 2.2x to 5.6x. Implied FV range: $400 million to $1,025 million.
Note: The filing does not provide consolidated revenue, profit, cash flow, debt, or liquidity metrics for Coherus BioSciences, Inc. as a whole, only prospective data for the UDENYCA asset being sold.
Material Changes and Process Details
Sales Process Expansion: The filing clarifies that between June 30, 2024, and July 16, 2024, J.P. Morgan contacted nine additional potential counterparties beyond those initially approached. Nine parties did not respond or declined interest. Six parties (including Intas) executed non-disclosure agreements (NDAs) with one-year "standstill" provisions.
Standstill Provisions:
- Two NDAs (including Accord) included "fall-away" provisions upon entry into a definitive agreement.
- One NDA included a fall-away provision upon consummation.
- Three parties with standstills lacking fall-away provisions either did not submit offers, withdrew, or submitted significantly lower proposals.
Legal Status: The Company has received demand letters and four complaints filed in the Supreme Court of the State of New York alleging disclosure deficiencies. The Company denies all allegations and asserts the claims are without merit but is providing this supplemental information voluntarily to avoid delaying the transaction.
Outlook, Risks, and Management Commentary
Management Stance: The Board and management believe the transaction is in the best interest of stockholders. The supplemental disclosures are made without admitting liability or wrongdoing to mitigate litigation risks and ensure the transaction closes.
Risks and Contingencies:
- Litigation Risk: Potential for additional demand letters or amended complaints. The outcome of current litigation is unpredictable, and the Company cannot estimate potential losses.
- Transaction Risk: The sale is contingent upon stockholder approval at the Special Meeting on March 11, 2025.
- Projection Risk: The financial projections for UDENYCA are forward-looking and based on management estimates and assumptions regarding market conditions and sales.
Investor Verification Checklist
- Stockholder Vote: Verify the outcome of the Special Meeting on March 11, 2025, regarding the approval of the Asset Purchase Agreement.
- Litigation Status: Monitor for updates on the four filed complaints and any additional demand letters that could delay or block the transaction.
- Valuation Assumptions: Review the specific probability estimates and discount rates (13.25%) used to calculate the $47 million risk-adjusted earnout value.
- Post-Transaction Strategy: Assess Coherus's remaining business pipeline and liquidity position after divesting the UDENYCA franchise, as this filing does not detail the company's broader financial health.
- Standstill Waivers: Confirm if any waivers were granted to other potential bidders during the process, as the Asset Purchase Agreement allows for such waivers under specific fiduciary conditions.